December 2014

Clinical Trials and the Wisdom of Crowds

Monday, December 22, 2014

The Pulse on Global Trials by Matthew Howes

I am writing this column from Basel, Switzerland, where I have been asked to share my experiences in leading innovation with an audience of 300 Roche employees.

[Read More]

14 indicted in connection with 2012 nationwide fungal meningitis outbreak

Friday, December 19, 2014

The Justice Department unsealed a 131-count criminal indictment in Boston in connection with the 2012 nationwide fungal meningitis outbreak. Barry J. Cadden, owner and head pharmacist of New England Compounding Center (NECC), and NECC’s supervisory pharmacist Glenn A. Chin were charged with 25 acts of second-degree murder in Florida, Indiana, Maryland, Michigan, North Carolina, Tennessee and Virginia.   

[Read More]

Roche acquires Bina Technologies, enters genomic informatics market

Friday, December 19, 2014

Roche has acquired Bina Technologies, a privately held company based in Redwood City, Calif. Bina provides a big data platform for centralized management and processing of next generation sequencing (NGS) data. Bina’s proprietary on-market Genomic Management Solution, Bina-GMS, empowers basic, translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data.

[Read More]

Merck acquires OncoEthix, a privately-held oncology company

Friday, December 19, 2014

Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based, privately held biotechnology company specializing in oncology drug development. Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, currently in phase Ib studies for the treatment of hematological malignancies and advanced solid tumors.

[Read More]

RXi Pharmaceuticals, Hapten Pharmaceuticals ink agreement

Friday, December 19, 2014

RXi Pharmaceuticals, a Marlborough, Mass.,-based biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, an early stage dermatology product development company based in New York, for the therapeutic use of Samcyprone.

[Read More]